Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP006
MIFTS: 49

Hypertensive Heart Disease

Categories: Blood diseases, Cardiovascular diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hypertensive Heart Disease

About this section

MalaCards integrated aliases for Hypertensive Heart Disease:

Name: Hypertensive Heart Disease 12 54 15 71 32

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:11516
ICD9CM 34 402
SNOMED-CT 67 64715009
ICD10 32 I11 I11.0 I11.9
UMLS 71 C0152105
Sources

Summaries for Hypertensive Heart Disease

About this section
Disease Ontology : 12 A heart disease that is caused by high blood pressure.

MalaCards based summary : Hypertensive Heart Disease is related to apnea, obstructive sleep and pre-eclampsia. An important gene associated with Hypertensive Heart Disease is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Cytokine Signaling in Immune system and p70S6K Signaling. The drugs Spironolactone and Hormone Antagonists have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and kidney, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Hypertensive heart disease includes a number of complications of high blood pressure that affect the... more...

Sources

Related Diseases for Hypertensive Heart Disease

About this section

Diseases related to Hypertensive Heart Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 234)
# Related Disease Score Top Affiliating Genes
1 apnea, obstructive sleep 31.9 NPPB IGF1 AGT ACE
2 pre-eclampsia 31.0 NPPA MMP9 MMP2 IGF1 ANXA5 AGTR1
3 cardiovascular system disease 30.8 NR3C2 NPPB NPPA IGF1 CYP11B2 AGTR1
4 atrial standstill 1 30.7 TPM1 NPPB NPPA ACE
5 ischemia 30.4 NPPB FGF2 CASP3 ACE
6 mitral valve insufficiency 30.3 NR3C2 NPPB NPPA ACE
7 nephrosclerosis 30.2 NR3C2 CASP3 AGTR1 ACE
8 mitral valve stenosis 30.2 NPPB NPPA ACE
9 renovascular hypertension 30.2 NPPB NPPA AGTR1 ACE
10 renal dysplasia 30.1 AGTR1 AGT ACE
11 sleep apnea 30.1 NPPB IGF1 AGT ACE
12 renal hypertension 30.1 NPPB AGTR1 AGT ACE
13 pericardial effusion 29.9 NPPB NPPA FGF2 ACE
14 muscle hypertrophy 29.9 NPPA MSTN IGF1 AGT
15 lipoprotein quantitative trait locus 29.9 NPPB NPPA MMP9 CASP3 AGTR1 ACE
16 heart valve disease 29.8 NR3C2 NPPB NPPA CTF1 ACE
17 congestive heart failure 29.7 NR3C2 NPR1 NPPB NPPA CYP11B2 AGTR1
18 familial hypertension 29.7 NR3C2 NPPA CYP11B2 AGTR1 AGT
19 arteriosclerosis 29.6 MMP9 FGF2 ANXA5 ACE
20 kidney disease 29.6 NR3C2 NPPB NPPA AGTR1 AGT ACE
21 malignant hypertension 29.6 NPPB NPPA AGTR1 AGT ACE
22 atrial fibrillation 29.6 NR3C2 NPPB NPPA CYP11B2 AGTR1 AGT
23 diastolic heart failure 29.5 NPPB NPPA MMP9 MMP2 MMP1 AGTR1
24 pulmonary hypertension 29.4 NPPB NPPA FGF2 CASP3 AGTR1 ACE
25 pulmonary edema 29.4 NR3C2 NPPB NPPA AGTR1 AGT ACE
26 autosomal dominant polycystic kidney disease 29.3 IGF1 CYP11B2 CASP3 AGTR1 AGT ACE
27 cerebrovascular disease 29.3 NPPB NPPA MMP9 AGTR1 AGT ACE
28 vascular disease 29.3 NPPB MMP9 IGF1 FGF2 CASP3 AGTR1
29 systolic heart failure 29.0 NR3C2 NPPB NPPA MMP9 MMP2 CYP11B2
30 body mass index quantitative trait locus 11 29.0 NR3C2 NPR1 MSTN IGF1 AGT ACE
31 hypertrophic cardiomyopathy 28.9 TPM1 NR3C2 NPPB NPPA MMP9 IGF1
32 heart disease 28.9 NR3C2 NPPB NPPA MSTN MMP9 IGF1
33 chronic kidney disease 28.9 NR3C2 NPPB NPPA MMP9 IGF1 CYP11B2
34 diabetes mellitus, noninsulin-dependent 28.7 NR3C2 MSTN MMP9 IGF1 CASP3 AGTR1
35 diabetes mellitus 28.6 NR3C2 NPPB MMP9 MMP2 IGF1 FGF2
36 hypertension, essential 28.1 NR3C2 NPR1 NPPB NPPA MMP9 MMP2
37 dilated cardiomyopathy 27.9 TPM1 TIMP2 NR3C2 NPPB NPPA MMP9
38 myocardial infarction 26.0 TIMP2 NR3C2 NPR1 NPPB NPPA MMP9
39 toxic myocarditis 10.5 NPPB ACE
40 chronic actinic dermatitis 10.5 MMP9 MMP1
41 extracranial arteriovenous malformation 10.5 MMP9 MMP2
42 focal myositis 10.5 MMP9 MMP2
43 cardiac tuberculosis 10.5 NR3C2 NPPB ACE
44 lentigo maligna melanoma 10.5 MMP9 MMP2
45 left bundle branch hemiblock 10.5 NR3C2 NPPB ACE
46 acute transverse myelitis 10.5 MMP9 MMP2
47 pneumococcal meningitis 10.5 MMP9 CASP3
48 fibromatosis, gingival, 1 10.4 MMP2 MMP1 CD36
49 posterior urethral valves 10.4 AGTR1 AGT ACE
50 pseudohyperkalemia, familial, 2, due to red cell leak 10.4 NR3C2 CYP11B2 ACE

Comorbidity relations with Hypertensive Heart Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Heart Disease
Hypertension, Essential

Graphical network of the top 20 diseases related to Hypertensive Heart Disease:



Diseases related to Hypertensive Heart Disease
Sources

Symptoms & Phenotypes for Hypertensive Heart Disease

About this section

MGI Mouse Phenotypes related to Hypertensive Heart Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.33 ACE AGT AGTR1 CASP3 CD36 CYP11B2
2 homeostasis/metabolism MP:0005376 10.3 ACE AGT AGTR1 CASP3 CD36 CTF1
3 hematopoietic system MP:0005397 10.25 ACE AGTR1 ANXA5 CASP3 CD36 CYP11B2
4 growth/size/body region MP:0005378 10.21 ACE AGT AGTR1 CASP3 CD36 CTF1
5 immune system MP:0005387 10.17 ACE AGT AGTR1 ANXA5 CASP3 CD36
6 adipose tissue MP:0005375 10.08 ACE AGT AGTR1 CD36 CTF1 CYP11B2
7 muscle MP:0005369 10 AGT CASP3 CD36 FGF2 IGF1 MMP2
8 nervous system MP:0003631 9.73 AGT AGTR1 CASP3 CD36 CTF1 CYP11B2
9 neoplasm MP:0002006 9.7 ACE FGF2 IGF1 MMP1 MMP2 MMP9
10 renal/urinary system MP:0005367 9.36 ACE AGT AGTR1 CASP3 CD36 CYP11B2
Sources

Drugs & Therapeutics for Hypertensive Heart Disease

About this section

Drugs for Hypertensive Heart Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
2 Hormone Antagonists Phase 4
3 Mineralocorticoids Phase 4
4 Hormones Phase 4
5 Mineralocorticoid Receptor Antagonists Phase 4
6 diuretics Phase 4
7 Diuretics, Potassium Sparing Phase 4
8
Irbesartan Approved, Investigational Phase 2, Phase 3 138402-11-6 3749
9
Atenolol Approved Phase 2, Phase 3 29122-68-7 2249
10
Enalapril Approved, Vet_approved Phase 3 75847-73-3 40466924 5362032
11
Enalaprilat Approved Phase 3 76420-72-9 6917719
12
Angiotensin II Approved, Investigational Phase 3 4474-91-3, 11128-99-7, 68521-88-0 172198
13
Valsartan Approved, Investigational Phase 3 137862-53-4 60846
14
Amlodipine Approved Phase 3 88150-42-9 2162
15
Hydrochlorothiazide Approved, Vet_approved Phase 3 58-93-5 3639
16
Vitamin D3 Approved, Nutraceutical Phase 2, Phase 3 67-97-0 5280795 6221
17
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 1406-16-2
18 Trace Elements Phase 2, Phase 3
19 Micronutrients Phase 2, Phase 3
20 Vitamins Phase 2, Phase 3
21 Nutrients Phase 2, Phase 3
22 Calciferol Phase 2, Phase 3
23 Calcium, Dietary Phase 2, Phase 3
24 Adrenergic beta-1 Receptor Antagonists Phase 2, Phase 3
25 Neurotransmitter Agents Phase 2, Phase 3
26 Adrenergic Antagonists Phase 2, Phase 3
27 Sympatholytics Phase 2, Phase 3
28 Adrenergic Agents Phase 2, Phase 3
29 Anti-Arrhythmia Agents Phase 2, Phase 3
30 Adrenergic beta-Antagonists Phase 2, Phase 3
31
protease inhibitors Phase 3
32 Angiotensin-Converting Enzyme Inhibitors Phase 3
33 HIV Protease Inhibitors Phase 3
34 Natriuretic Peptide, Brain Phase 2, Phase 3
35 Angiotensin II Type 1 Receptor Blockers Phase 3
36 Angiotensinogen Phase 3
37 Angiotensin Receptor Antagonists Phase 3
38 Antihypertensive Agents Phase 3
39 Giapreza Phase 3
40 LCZ 696 Phase 3
41
Calcium Nutraceutical Phase 2, Phase 3 7440-70-2 271
42 Pharmaceutical Solutions Phase 2
43 Adjuvants, Immunologic Phase 2
44 Antioxidants Phase 2
45 Pycnogenols Phase 2
46 Immunologic Factors Phase 2
47 Platelet Aggregation Inhibitors Phase 2
48 Protective Agents Phase 2
49
Eplerenone Approved 107724-20-9 150310 443872
50
Atorvastatin Approved 134523-00-5 60823

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart Completed NCT01944384 Phase 4 aldactone
2 Impact of Vitamin D Supplementation on Cardiac Hypertrophy and Function in Chronic Kidney Disease Patients - a Randomised Controlled Trial Unknown status NCT01323712 Phase 2, Phase 3
3 Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease Completed NCT00865501 Phase 3 spironolactone;placebo
4 Stress Reduction and Atherosclerotic CVD in Blacks Completed NCT00000546 Phase 3
5 Randomized, Double-blind Evaluation of the Effects of Irbesartan and Atenolol on Cardiovascular Structure and Function in Subjects With Hypertension and Left Ventricular Hypertrophy Completed NCT00389168 Phase 2, Phase 3 Irbesartan;Atenolol
6 Hypertension Detection and Follow-up Program (HDFP) Completed NCT00000485 Phase 3 diuretics;antihypertensive agents
7 Studies of Left Ventricular Dysfunction (SOLVD) Completed NCT00000516 Phase 3 enalapril
8 A Randomized Trial of Pocket-Echocardiography Integrated Mobile Health Device Assessments in Modern Structural Heart Disease Clinics Completed NCT02881398 Phase 2, Phase 3
9 Role of ARNi in Ventricular Remodeling in Hypertensive LVH Not yet recruiting NCT03553810 Phase 3 Entresto;Valsartan
10 Regress-HFPEF: Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFPEF Patients Treated With Allogeneic CDCs Recruiting NCT02941705 Phase 2
11 Mechanism of the Anti-remodeling Activity of the Over-the-counter Dietary Supplement, Pycnogenol, on Age-dependent Process of Cardiac Fibrosis in Aged Hypertensive Subjects With Echocardiographic Evidence of Grade I/II Diastolic Dysfunction Terminated NCT00952627 Phase 2
12 E_Stethoscope : Portable Digital Auscultation Based on Wireless Sensor Node to Diagnose Diastolic Dysfunction in Hypertensive Heart Disease Unknown status NCT02809040
13 Response of the Myocardium to Hypertrophic Conditions in the Adult Population Unknown status NCT02670031
14 Invasive Findings in Patients With Angina Equivalent Symptoms But No Coronary Artery Disease; Results From the Heart Quest Cohort Study Unknown status NCT01318629
15 Predictive Factors of Systolic Dysfunction in Non-complicated Hypertensive Patients (GLS OBservationAL Study in HyperTensioN - GLOBAL-HTN) Unknown status NCT02841696
16 Prospective Randomized Controlled Clinical Study Comparing Two Bariatric Bypass Procedures, Roux-en-Y Gastric Bypass (RYGB) and Omega-Loop Gastric Bypass (OLGB), in Patients With Severe Obesity and Metabolic Disease Unknown status NCT02290418
17 The Role of Functional Active Anti-Angiotensin-Receptor 1 (ATR1)- and Anti-Endothelin-Receptor A (ETRA)-Antibodies and Autoreactive T Cells in Cardiomyopathy Unknown status NCT02319590
18 Adjunct Vitamin D Therapy as a Means to Reduce the Disparity in Subclinical Target Organ Cardiac Damage Among Vulnerable Hypertensive Patients Completed NCT01360476
19 Cardiac Dysfunction in Adolescents With Type 1 Diabetes: Contribution of Daily-life Glucoregulation and Impact on Cardiorespiratory Exercise Capacity Completed NCT04052919
20 Biobehavioral Mechanisms of Blood Pressure Regulation Completed NCT00005366
21 Prevention of Cardiovascular Stiffening With Aging and Hypertensive Heart Disease Completed NCT03476785
22 Crossover Comparison of Treatment With Continuous Positive Airway Pressure and Treatment With Adaptive Servo Ventilation (SOMNOventCR) in Patients With Underlying Heart Disease, Combined Obstructive Sleep Apnea and Cheyne-Stokes Respiration. Completed NCT00811668
23 Asian American Partnerships in Research and Empowerment (AsPIRE) Completed NCT03100812
24 Pulmonary Abnormalities, Diastolic Dysfunction, and World Trade Center Exposure: Implications for Diagnosis and Treatment Completed NCT01466218
25 The Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart Failure Completed NCT00505336 Eplerenone;Atorvastatin
26 Impedance Cardiography in the Evaluation of Left Ventricular Diastolic Dysfunction in Patients With Arterial Hypertension Study (IMPEDDANS) Completed NCT03209141
27 Tilt Table and Autonomic Testing in Suspected POTS Subjects Completed NCT01617616
28 EARLY Differentiation of MYOcardial Hypertrophy From Hypertensive Heart Disease: a Multi-center, Prospective, Controlled Clinical Trial Recruiting NCT03271385
29 Renal Sympathetic Denervation Restores Autonomic Imbalance and Prevents Atrial Fibrillation in Patients With Hypertensive Heart Disease: a Pilot Study Recruiting NCT01990911 Medical therapy
30 The Transition From Hypertension to Hypertensive Heart Disease and Heart Failure, the PREFERS Hypertension Study Enrolling by invitation NCT04190420

Search NIH Clinical Center for Hypertensive Heart Disease

Sources

Genetic Tests for Hypertensive Heart Disease

About this section
Sources

Anatomical Context for Hypertensive Heart Disease

About this section

MalaCards organs/tissues related to Hypertensive Heart Disease:

40
Heart, Testes, Kidney, Brain, T Cells, Endothelial, Bone Marrow
Sources

Publications for Hypertensive Heart Disease

About this section

Articles related to Hypertensive Heart Disease:

(show top 50) (show all 1555)
# Title Authors PMID Year
1
Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure. 54 61
19887955 2009
2
Functional polymorphisms in ACE and CYP11B2 genes and atrial fibrillation in patients with hypertensive heart disease. 61 54
19117407 2009
3
Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. 54 61
18086943 2008
4
Tiotropium, a novel muscarinic M3 receptor antagonist, improved symptoms of chronic obstructive pulmonary disease complicated by chronic heart failure. 61 54
17127817 2006
5
Measurements of baseline and follow-up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure from various etiologies. 61 54
17143708 2006
6
Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease. 54 61
16371224 2006
7
Comparison of positive cases for B-type natriuretic peptide and ECG testing for identification of precursor forms of heart failure in an elderly population. 54 61
16043943 2005
8
Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. 54 61
15313958 2004
9
Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. 61 54
15093887 2004
10
Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. 61 54
15202614 2004
11
Peroxisome proliferator-activated receptor alpha and hypertensive heart disease. 54 61
15765888 2004
12
The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. 54 61
14597852 2003
13
Natriuretic peptide receptor A mediates renal sodium excretory responses to blood volume expansion. 54 61
12824076 2003
14
Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. 61 54
11569573 2001
15
Renin-angiotensin system inhibition improves coronary flow reserve in hypertension. 54 61
11392478 2001
16
Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. 54 61
10948081 2000
17
AT1 receptors: coronary flow and flow reserve. 54 61
10678287 2000
18
[Hypertensive heart disease with left ventricular diastolic dysfunction demonstrating restrictive hemodynamics: a case report]. 61 54
10396707 1999
19
Angiotensin converting enzyme inhibition by captopril influences cardiac work in healthy hearts. 61 54
9832171 1998
20
Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. 54 61
9405681 1997
21
Effects of moexiprilat on oestrogen-stimulated cardiac fibroblast growth. 61 54
9257913 1997
22
Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. 54 61
8890821 1996
23
Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: in vivo and in vitro studies on collagen matrix regulation. 61 54
8518539 1993
24
Increased Susceptibility of Mice Lacking Renin-b to Angiotensin II-Induced Organ Damage. 61
32507043 2020
25
Mind the gaps: age and cause specific mortality and life expectancy in the older population of South Korea and Japan. 61
32487053 2020
26
Evidence of structural and functional plasticity occurring within the intracardiac nervous system of spontaneously hypertensive rats. 61
32357112 2020
27
Interplay of cardiac remodelling and myocardial stiffness in hypertensive heart disease: a shear wave imaging study using high-frame rate echocardiography. 61
31377789 2020
28
Sensitive marker for evaluation of hypertensive heart disease: extracellular volume and myocardial strain. 61
32539749 2020
29
Tandospirone enhances the anti-myocardial fibrosis effect of valsartan in spontaneously hypertensive rats. 61
32179201 2020
30
Basal Ventricular Septal Hypertrophy in Systemic Hypertension. 61
32164912 2020
31
Cardioprotective Effects of the Novel Compound Vastiras in a Preclinical Model of End-Organ Damage. 61
32200677 2020
32
Sporadic inclusion body myositis: no specific cardiac involvement in cardiac magnetic resonance tomography. 61
31997038 2020
33
Maternal cardiovascular risk after hypertensive disorder of pregnancy. 61
32404402 2020
34
Efficacy and complications of cavo-tricuspid isthmus-dependent atrial flutter ablation in patients with and without structural heart disease: results from the German Ablation Registry. 61
32458180 2020
35
Inhibition of Interleukin-6/glycoprotein 130 signalling by Bazedoxifene ameliorates cardiac remodelling in pressure overload mice. 61
32164044 2020
36
Circulating biomarkers in the early detection of hypertensive heart disease: usefulness in the developing world. 61
32420112 2020
37
The transition from hypertension to hypertensive heart disease and heart failure: the PREFERS Hypertension study. 61
32073753 2020
38
Differences in clinical characteristics and outcome of de novo heart failure compared to acutely decompensated chronic heart failure - systematic review and meta-analysis. 61
32252602 2020
39
Re: Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost-effectiveness Analysis. 61
32282117 2020
40
Altered heart rate variability in angiotensin II-mediated hypertension is associated with impaired autonomic nervous system signaling and intrinsic sinoatrial node dysfunction. 61
32224266 2020
41
Characteristics of current heart failure patients admitted to internal medicine vs. cardiology hospital units: the VASCO study. 61
32172459 2020
42
Time Trends in Cardiovascular Disease Mortality Across the BRICS: An Age-Period-Cohort Analysis of Key Nations With Emerging Economies Using the Global Burden of Disease Study 2017. 61
31941371 2020
43
Left ventricular hypertrophy in athletes: How to differentiate between hypertensive heart disease and athlete's heart. 61
32208752 2020
44
Comprehensive assessment of hypertensive heart disease: cardiac magnetic resonance in focus. 61
32170529 2020
45
Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment. 61
31759935 2020
46
The Effect of Antihypertensive Therapy on Left Ventricular Longitudinal Strain: Missing Part of the Puzzle. 61
32086702 2020
47
Analysis of mast cells and myocardial fibrosis in autopsied patients with hypertensive heart disease. 61
32205013 2020
48
Mast cells: Promoters of myocardial fibrosis in hypertensive heart disease? 61
32248991 2020
49
A young patient with left ventricular hypertrophy and accidentally discovered aortic dissection: hypertensive heart disease or hypertrophic cardiomyopathy? 61
31994492 2020
50
Worldwide disease epidemiology in the older persons. 61
32297233 2020
Sources

Variations for Hypertensive Heart Disease

About this section
Sources

Expression for Hypertensive Heart Disease

About this section
Search GEO for disease gene expression data for Hypertensive Heart Disease.
Sources

Pathways for Hypertensive Heart Disease

About this section

Pathways related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 65
Show member pathways
 13.3 MMP9 MMP2 MMP1 FGF2 CTF1 CD36
2
p70S6K Signaling 63
Show member pathways
 12.98 TIMP2 IGF1 FGF2 AGTR1 AGT ACE
3
Degradation of the extracellular matrix 65
Show member pathways
 12.67 TIMP2 MMP9 MMP2 MMP1 FGF2 CASP3
4
Pathways in cancer 36
12.58 MMP9 MMP2 MMP1 IGF1 FGF2 CASP3
5
Oxytocin signaling pathway 36
Show member pathways
 12.43 NPR1 NPPB NPPA AGTR1 AGT
6
cGMP-PKG signaling pathway 36
Show member pathways
 12.41 TPM1 NPR1 NPPB NPPA AGTR1 AGT
7
Proteoglycans in cancer 36
12.19 MMP9 MMP2 IGF1 FGF2 CASP3
8
Dilated cardiomyopathy (DCM) 36
Show member pathways
 12.18 TPM1 IGF1 AGT ACE
9
Colorectal Cancer Metastasis 63
12.12 MMP9 MMP2 MMP1 CASP3
10
AGE-RAGE signaling pathway in diabetic complications 36
11.87 MMP2 CASP3 AGTR1 AGT
11
Interleukin-4 and 13 signaling 65
11.86 MMP9 MMP2 MMP1 FGF2 CD36
12
Matrix Metalloproteinases 1
Show member pathways
 11.85 TIMP2 MMP9 MMP2 MMP1
13
Angiogenesis (CST) 4
11.76 TIMP2 MMP9 MMP2 FGF2
14
Bladder cancer 36 1
11.68 MMP9 MMP2 MMP1
15
AGE/RAGE pathway 1
11.63 MMP9 MMP2 CASP3
16
MicroRNAs in cardiomyocyte hypertrophy 1
Show member pathways
 11.63 NPPB NPPA IGF1 FGF2 CTF1 AGT
17
LPA receptor mediated events 1
11.62 MMP9 MMP2 CASP3
18
Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics 60
Show member pathways
 11.62 NR3C2 CYP11B2 AGTR1 AGT ACE
19
Endochondral Ossification 1
11.61 MMP9 IGF1 FGF2
20
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.59 MMP9 MMP2 MMP1
21
Lung fibrosis 1
11.56 MMP9 MMP2 IGF1 FGF2
22
Renin secretion 36
11.39 NPR1 NPPA AGTR1 AGT ACE
23
Cell adhesion_Cell-matrix glycoconjugates 22
11.36 TIMP2 MMP9 MMP1
24
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.29 MMP9 MMP2 MMP1
25
A-beta Uptake and Degradation 64
11.17 MMP9 MMP2 CD36 ACE
26
Angiogenesis (WikiPathways) 1
11.1 TIMP2 MMP9 FGF2
27
A-beta Plaque Formation and APP Metabolism 64
11.06 MMP9 MMP2 ACE
28
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 65
10.99 MMP2 MMP1 IGF1
29
Cell adhesion_ECM remodeling 22
10.81 TIMP2 MMP9 MMP2 MMP1 IGF1
Sources

GO Terms for Hypertensive Heart Disease

About this section

Cellular components related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TIMP2 NPPB NPPA MSTN MMP9 MMP2
2 collagen-containing extracellular matrix GO:0062023 9.63 TIMP2 NPPA MMP9 MMP2 ANXA5 AGT
3 extracellular matrix GO:0031012 9.56 TIMP2 MMP9 MMP2 MMP1
4 extracellular space GO:0005615 9.4 TIMP2 NPPB NPPA MSTN MMP9 MMP2

Biological processes related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.97 NPR1 NPPB CTF1 CD36 AGT
2 extracellular matrix organization GO:0030198 9.95 MMP9 MMP2 MMP1 FGF2
3 cellular protein metabolic process GO:0044267 9.94 NPPA MMP2 MMP1 IGF1
4 negative regulation of cell growth GO:0030308 9.86 NPR1 NPPB NPPA AGT
5 wound healing GO:0042060 9.85 TPM1 CASP3 FGF2
6 positive regulation of MAPK cascade GO:0043410 9.85 TIMP2 IGF1 FGF2 CD36
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 IGF1 CD36 AGT
8 response to organic substance GO:0010033 9.83 TIMP2 CASP3 ANXA5
9 regulation of cardiac conduction GO:1903779 9.79 NPR1 NPPA AGT
10 collagen catabolic process GO:0030574 9.78 MMP9 MMP2 MMP1
11 extracellular matrix disassembly GO:0022617 9.78 TIMP2 MMP9 MMP2 MMP1
12 cellular response to reactive oxygen species GO:0034614 9.76 TPM1 MMP9 MMP2
13 positive regulation of reactive oxygen species metabolic process GO:2000379 9.71 CD36 AGTR1 AGT
14 cytokine-mediated signaling pathway GO:0019221 9.7 MMP9 MMP2 MMP1 FGF2 CTF1 CD36
15 regulation of vasoconstriction GO:0019229 9.69 AGTR1 AGT ACE
16 response to amyloid-beta GO:1904645 9.67 MMP9 MMP2
17 positive regulation of urine volume GO:0035810 9.67 NPR1 NPPB
18 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.67 CD36 AGTR1 AGT
19 low-density lipoprotein particle remodeling GO:0034374 9.66 AGTR1 AGT
20 negative regulation of systemic arterial blood pressure GO:0003085 9.66 NPPB NPPA
21 regulation of vascular permeability GO:0043114 9.64 NPR1 NPPB
22 positive regulation of cholesterol esterification GO:0010873 9.63 AGTR1 AGT
23 body fluid secretion GO:0007589 9.63 NPR1 NPPB
24 positive regulation of renal sodium excretion GO:0035815 9.63 NPR1 NPPB AGT
25 positive regulation of NAD(P)H oxidase activity GO:0033864 9.62 AGTR1 AGT
26 positive regulation of cGMP-mediated signaling GO:0010753 9.62 NPR1 NPPA
27 cGMP-mediated signaling GO:0019934 9.62 NPR1 NPPB NPPA CD36
28 cGMP biosynthetic process GO:0006182 9.61 NPR1 NPPB NPPA
29 regulation of renal sodium excretion GO:0035813 9.6 AGTR1 AGT
30 renin-angiotensin regulation of aldosterone production GO:0002018 9.59 AGTR1 AGT
31 receptor guanylyl cyclase signaling pathway GO:0007168 9.58 NPR1 NPPB NPPA
32 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.57 AGTR1 AGT
33 regulation of blood vessel diameter GO:0097746 9.56 NPR1 NPPB AGTR1 ACE
34 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.54 AGTR1 AGT ACE
35 regulation of renal output by angiotensin GO:0002019 9.52 AGT ACE
36 regulation of blood pressure GO:0008217 9.35 NPR1 NPPB NPPA AGT ACE
37 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.02 MMP9 MMP2 IGF1 FGF2 AGT

Molecular functions related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.88 TIMP2 NR3C2 MMP9 MMP2 MMP1 ACE
2 peptidase activity GO:0008233 9.83 MMP9 MMP2 MMP1 CASP3 ACE
3 metallopeptidase activity GO:0008237 9.62 MMP9 MMP2 MMP1 ACE
4 growth factor activity GO:0008083 9.56 MSTN IGF1 FGF2 AGT
5 hormone activity GO:0005179 9.46 NPPB NPPA IGF1 AGT
6 hormone receptor binding GO:0051427 9.37 NPPB NPPA
7 bradykinin receptor binding GO:0031711 8.96 AGTR1 ACE
8 endopeptidase activity GO:0004175 8.92 MMP9 MMP2 MMP1 ACE
Sources

Sources for Hypertensive Heart Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....